ReviewFrontiers in endocrinology2026
Hemochromatosis osteoarthritis.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemochromatosis-associated arthropathy is a progressive degenerative joint disease characterized by iron-overload related pathological changes. While it may involve episodic inflammatory flares, it is primarily defined by bone and cartilage destruction rather than persistent chronic synovitis. It is typically classified as either spontaneous or secondary. This condition is often accompanied by various clinical manifestations, including liver disease, cardiomyopathy, skin pigmentation changes, diabetes mellitus, erectile dysfunction, and hypothyroidism. Diagnosis typically relies on a combination of imaging techniques such as x-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, along with iron function tests and joint fluid analysis. Genetic testing may also serve as an adjunctive diagnostic tool. The main treatment modalities currently available include phlebotomy (the primary therapy for hereditary hemochromatosis), iron chelators, joint cavity drug injections, and surgical interventions. Lastly, we delve into the preventative measures that can be adopted to mitigate the risk of developing this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.